BioCentury | Nov 14, 2020

Jeito adds dry powder to invest in European innovation

French VC Jeito has added a second strategic investor, this time a little closer to home. Sanofi (Euronext:SAN; NASDAQ:SNY) invested €50 million ($59 million), marking the pharma’s first investment into...
BioCentury | Nov 13, 2020
Translation in Brief

Roche and Immune-Onc mAb data; plus Capricor’s exosome-based COVID-19 vaccine induces cellular immunity, and more

Roche’s mAb depletes regulatory T cellsRoche (SIX:ROG; OTCQX:RHHBY) and University College London scientists reported in Nature Cancer that the anti-CD25 mAb RG6292, which is in a Phase I trial in advanced...
BioCentury | Oct 24, 2020
Emerging Company Profile

SparingVision’s line of sight to a mutation-agnostic gene therapy for ophthalmic disease

SparingVision thinks its neuroprotective AAV therapy could benefit all retinitis pigmentosa patients, including those missed by mutation-targeted gene replacement therapies like Luxturna. The Paris-based...
BioCentury | Aug 27, 2020
Distillery Therapeutics

A collagen receptor as an Alzheimer’s target

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease (AD) Blocking the collagen receptor GP6 could treat Alzheimer’s disease by reducing platelet-associate β amyloid aggregation. In vitro, platelets...
BioCentury | Jul 11, 2020
Management Tracks

Andrews joins Akcea as CMO; plus changes at Strongbridge, Abeona, Lyra, Kronos and more

Akcea Therapeutics Inc. (NASDAQ:AKCA) said William Andrews will succeed Louis O’Dea as CMO. Andrews joins the rare disease company from Acer Therapeutics Inc. (NASDAQ:ACER), where he was CMO. Rare disease company Strongbridge Biopharma plc (NASDAQ:SBBP)...
BioCentury | Jul 3, 2020
Management Tracks

Angus Grant joins BeiGene; plus changes at Sarepta, RegenxBio, BioMarin, Novavax, Whitehead, Akcea and more

BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Angus Grant as chief business executive, a new position at the cancer company. He was CEO of the Dementia Discovery Fund. After eight years with Sarepta Therapeutics Inc. (NASDAQ:SRPT), EVP,...
BioCentury | May 28, 2020

May 27 Quick Takes: Atara raises $176M on back of MS data; plus Exscientia’s $60M C round, Geron, Silence, Arvelle, ViaCyte, Poxel, Accure, Tollys

Atara follows Phase I MS data with $178M offering Atara Biotherapeutics Inc. (NASDAQ:ATRA) raised $175.5 million in a follow-on a day after reporting Phase I data ATA188 reduced disability in multiple sclerosis patients. The company’s...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
BioCentury | Apr 2, 2020

Dynacure taps U.S. crossovers in €50M series C to fund orphan muscle disease studies

Dynacure expects its €50 million ($55.4 million) series C round to fund an ongoing trial of its lead program for myotubular and centronuclear myopathies in adults, as well as a planned pediatric study. Together, the...
BioCentury | Mar 19, 2020
Product Development

DARPA’s gambles might have created the best hopes for stopping COVID-19

A U.S. defense agency that specializes in turning science fantasies into realities jump-started technologies and nurtured companies that are now at the forefront of the response to the COVID-19 pandemic. The Defense Research Advanced Projects...
Items per page:
1 - 10 of 599